Product Images Lorbrena

This is a comparison of two drugs, Lorbrena (N=149) and Crizotinib (N=147), in the treatment of cancer. The median survival time for patients taking Lorbrena has not been reached, whereas for those taking Crizotinib it was 9.3 months. The hazard ratio of Lorbrena versus Crizotinib was 0.28, with a 95% confidence interval of 0.19 to 0.41, and a p-value of less than 0.0001. The graph shows the survival curves for the two drugs over time.*

This is a description for a medicine, which is being distributed by Pfizer Labs. Pfizer Labs is a division of Pfizer Inc, located in New York City, with a zip code of 10017.*

This text is a description of the distributor of a product, Pfizer Labs, which is a division of Pfizer Inc, located in New York City.*

This is a prescription drug called Lorbrena (lorlatinib) tablets that comes in a bottle with 30 tablets each containing 25 mg and should be stored at 20°C to 25°C. It should be dispensed in tight, child-resistant containers. The prescribing information should be consulted for dosage and use. The drug is made in Ireland and distributed by Pfizer Labs. The NDC is 0069-0227-01. The other text is not-available or irrelevant.*

This is a prescription drug called Lorbrena® (lorlatinib) available in tablet form with a strength of 100 mg. It is to be stored at a temperature range of 20°C to 25°C (68°F to 77°F), and can be dispensed in tight, child-resistant containers. For more information on dosage and usage, please refer to the accompanying prescribing information. The drug is distributed by Pfizer Labs, a division of Pfizer Inc, and is made in Ireland. The National Drug Code (NDC) for this drug is 0069-0231-01. The remaining text is either illegible or non-English characters.*